ASA tablets p / o enteric 75mg №10×3

Name:
ASK tabl.coated.c/r obol.75mg in the cell.box No. 10×3
Description:
Round biconvex tablets of red color, film-coated. The main active ingredient Acetylsalicylic acid Form release Enteric-coated tablets Dosage 75 mg Special instructions and precautions The drug is used with caution in: hypersensitivity to analgesic, anti-inflammatory, antirheumatic drugs, as well as in the presence of allergies to other substances; ulcers of the gastrointestinal tract, including chronic and recurrent or history of gastrointestinal bleeding; simultaneous use of anticoagulants; impaired renal and / or liver function. In case of prolonged use of the drug, the patient should consult a doctor before starting ibuprofen. In patients with allergic complications, including bronchial asthma, allergic rhinitis, urticaria, pruritus, mucosal edema and nasal polyposis, as well as their combination with chronic respiratory tract infections and in patients with hypersensitivity to NSAIDs during treatment with acetylsalicylic acid possible development of bronchospasm or an attack of bronchial asthma. During surgical operations (including dental), the use of drugs containing acetylsalicylic acid may increase the likelihood of the appearance / increase in bleeding. When using small doses of acetylsalicylic acid, the excretion of uric acid may decrease. This can lead to gout in patients with reduced uric acid excretion. During treatment with acetylsalicylic acid, alcohol should not be consumed, given the increased risk of damage to the mucous membrane of the gastrointestinal tract. Pharmacological properties Acetylsalicylic acid inhibits platelet aggregation, and also has antipyretic, analgesic and anti-inflammatory effects. Aggregation is inhibited even after the use of the drug in low doses, the effect persists for several days after taking a single dose. Enteric-coated tablets are a pharmaceutical form that does not disintegrate in the stomach, and thus reduces the risk of direct contact of acetylsalicylic acid with the gastric mucosa and damage to it. The disintegration of the tablet and the release of the active substance occurs only in the environment of the duodenum. Indications for use To reduce the risk of: death in patients with suspected acute myocardial infarction; death in patients with a history of myocardial infarction; transient ischemic attacks (TIA) and stroke in patients with TIA; morbidity and death in stable and unstable angina. For the prevention of: thrombosis and embolism after vascular surgery (percutaneous transluminal catheter angioplasty (PTCA), carotid endarterectomy, coronary artery bypass grafting (CABG), arteriovenous bypass grafting); deep vein thrombosis and pulmonary embolism after prolonged immobilization (post-surgical operations); myocardial infarction in patients at high risk the development of cardiovascular complications (diabetes mellitus, controlled arterial hypertension) and persons with a multifactorial risk of cardiovascular diseases (hyperlipidemia, obesity, smoking, old age, etc.). For secondary prevention of stroke. Dosage and administration Adults are usually prescribed 1-2 tablets of 75 mg or 1 tablet of 150 mg per day during or after meals. Tablets should be swallowed whole with a small amount of water. For recent myocardial infarction or for patients with suspected myocardial infarction: the initial loading dose is 225-300 mg of acetylsalicylic acid 1 time per day in order to achieve a rapid suppression of platelet aggregation. A dosage of 300 mg per day can be used for short-term therapeutic indications. Tablets can be chewed for faster absorption. Use during pregnancy and lactation The drug can be used during pregnancy only when other drugs are ineffective. The use of salicylates in the first trimester of pregnancy in the case of some retrospective epidemiological studies was associated with an increased risk of developing congenital malformations (palatosis (“cleft palate”), heart defects). However, with long-term use of the drug in therapeutic doses exceeding 150 mg / day, this risk turned out to be low: as a result of a study conducted on 32,000 mother-child pairs, no association was found between the use of acetylsalicylic acid and an increase in the number of congenital malformations. Salicylates can be used in the I and II trimesters of pregnancy only after assessing the risk/benefit ratio. According to preliminary estimates, with long-term use of the drug, it is advisable not to take acetylsalicylic acid at a dose exceeding 150 mg / day. In the third trimester of pregnancy, high doses of salicylates (more than 300 mg/day) can cause pregnancy delay and weakening of contractions during childbirth, and can also lead to cardiopulmonary toxicity (premature closure of the ductus arteriosus) in children. The use of acetylsalicylic acid in large doses shortly before delivery can lead to intracranial bleeding, especially in premature babies. Thus, except in extremely special cases, stipulated by cardiac or obstetric medical indications based on special monitoring, the use of acetylsalicylic acid during the last trimester of pregnancy is contraindicated. Acetylsalicylic acid and its metabolites are excreted in small amounts in the breast milk of lactating women. So far, with short-term use of salicylates by mothers, the onset of undesirable effects in children who are breastfed has not been established; as a rule, there is no need to stop breastfeeding. However, in the case of prolonged use of high doses of acetylsalicylic acid, breastfeeding should be discontinued. Application in children Do not use preparations containing acetylsalicylic acid in children with acute respiratory viral infection (ARVI), which is accompanied or not accompanied by fever. Some viral illnesses, especially influenza A, influenza B, and chickenpox, are at risk of developing Reye’s syndrome, which is a very rare but life-threatening disease that requires urgent medical attention. The risk may be increased if acetylsalicylic acid is used as a concomitant drug, but a causal relationship has not been proven in this case. If these conditions are accompanied by prolonged vomiting, this may be a sign of Reye’s syndrome. Given the above reasons, children under 16 years of age are contraindicated in the use of the drug without special indications (Kawasaki disease). Influence on the ability to drive vehicles and control mechanisms The drug ASA does not affect the ability to drive vehicles and control mechanisms. Interaction with other drugs Contraindicated the use of acetylsalicylic acid simultaneously with methotrexate at doses of 15 mg / week or more, due to increased hematological toxicity of methotrexate (reduction in renal clearance of methotrexate by anti-inflammatory agents and displacement of methotrexate by salicylates from plasma proteins). Combinations that should be used with caution: use with methotrexate at doses less than 15 mg / week increases the hematological toxicity of methotrexate (reduction in renal clearance of methotrexate by anti-inflammatory agents and displacement of methotrexate from plasma protein binding by salicylates). Simultaneous use of ibuprofen prevents irreversible suppression of platelets by acetylsalicylic acid. Treatment with ibuprofen in patients at risk of cardiovascular disease may limit the cardioprotective effect of acetylsalicylic acid. With the simultaneous use of the drug and anticoagulants, the risk of bleeding increases. With the simultaneous use of high doses of salicylates with NSAIDs (due to a mutually exclusive effect), the risk of ulcers and gastrointestinal bleeding increases. Simultaneous use with uricosuric agents such as benzobromarone, probenecid reduces the effect of excretion of uric acid (due to competition for the excretion of uric acid by the renal tubules) .with simultaneous use with digoxin, the concentration of the latter in the blood plasma increases due to a decrease in renal excretion. with the simultaneous use of high doses of acetylsalicylic acid and oral antidiabetic drugs from the group of sulfonylurea or insulin derivatives, the hypoglycemic effect of the latter increases due to the hypoglycemic effect of acetylsalicylic acid and the displacement of sulfonylurea associated with plasma proteins. Diuretics in combination with high doses of acetylsalicylic acid reduce glomerular filtration due to a decrease in the synthesis of prostaglandins in the kidneys. cocorticosteroids (with the exception of hydrocortisone), used for replacement therapy in Addison’s disease, during the period of treatment with corticosteroids reduce the level of salicylates in the blood and increase the risk of overdose after the end of treatment. When used with corticosteroids, the risk of gastrointestinal bleeding increases. Selective serotonin reuptake inhibitors: the risk of bleeding from the upper gastrointestinal tract increases due to the possibility of a synergistic effect. ACE inhibitors (ACE) in combination with high doses of acetylsalicylic acid cause a decrease in filtration in glomeruli due to inhibition of vasodilatory prostaglandins and a decrease in the antihypertensive effect. When used simultaneously with valproic acid, acetylsalicylic acid displaces it from its association with plasma proteins, increasing the toxicity of the latter. . Contraindications Hypersensitivity to acetylsalicylic acid, other salicylates or any component of the drug. Chronic asthma caused by a history of salicylates or NSAIDs. Acute peptic ulcers. Hemorrhagic diathesis. Severe renal failure. Severe liver failure. Severe heart failure. a week or more. Composition Each tablet contains: active substance: acetylsalicylic acid – 75 mg or 150 mg; excipients: corn starch, crospovidone (Polyplasdon XL-10), talc, microcrystalline cellulose. shell composition: Advantia Preferred® (hydroxypropyl methylcellulose, copovidone, polydextrose, propylene glycol, medium chain triglycerides, titanium dioxide, iron oxide yellow), Advantia Performance® (copolymer of methacrylic acid and ethyl acrylate, talc, titanium dioxide, triethyl citrate, silicon dioxide, orange yellow E 110, charming red E 129). Overdose An overdose of salicylates is possible due to chronic intoxication resulting from prolonged therapy, as well as due to acute intoxication, which is life-threatening (overdose), and the causes of which may, for example, be accidental use by children or unexpected overdose. The first symptoms of intoxication with acetylsalicylic acid are dizziness, nausea, vomiting, tinnitus and shortness of breath, imbalance. Other symptoms were also observed: hearing loss, visual impairment, headache, increased sweating, motor agitation, drowsiness and coma, convulsions, hyperthermia, confusion. Chronic poisoning with salicylates may be latent, since its signs and symptoms are nonspecific. In case of taking a larger dose of the drug than recommended, you should immediately consult a doctor, and in case of acute poisoning, you should immediately go to the hospital. An overdose of the drug in elderly patients and in young children (taking more than recommended doses or accidental poisoning) requires special attention, since in these groups of patients it can lead to death. In severe intoxication, acid-base balance and water-electrolyte balance are disturbed (metabolic acidosis and dehydration). There is no specific antidote. Side effects On the part of the gastrointestinal tract, there is dyspepsia, pain in the epigastric region and abdominal pain, in some cases – inflammation of the gastrointestinal tract, clinical manifestations of erosive and ulcerative lesions of the gastrointestinal tract, which can, in rare cases, cause gastrointestinal hemorrhages and perforations with relevant laboratory parameters. Due to the antiplatelet effect on platelets, acetylsalicylic acid may increase the risk of bleeding. Bleeding such as intraoperative hemorrhages, hematomas, bleeding from the genitourinary system, nosebleeds, bleeding from the gums, rarely or very rarely – serious bleeding such as gastrointestinal hemorrhages, cerebral hemorrhages (especially in patients with uncontrolled hypertension and / or with simultaneous use of antihemostatic agents), in rare cases could be potentially life-threatening. Hemorrhages can lead to acute and chronic post-hemorrhagic anemia/iron deficiency anemia (due to the so-called latent microbleeding) with relevant laboratory findings and clinical symptoms such as asthenia, pallor of the skin, hypoperfusion. Patients with individual hypersensitivity to salicylates may develop allergic skin reactions, including symptoms such as rash, urticaria, swelling, itching. In patients with bronchial asthma, an increase in the incidence of bronchospasm is possible; minor to moderate allergic reactions potentially affect the skin, respiratory tract, gastrointestinal tract, and cardiovascular system. Very rarely, severe reactions, including anaphylactic shock, have been observed. Rarely – transient liver failure with an increase in the level of liver transaminases. Dizziness and ringing in the ears were observed, which may indicate an overdose. Storage conditions Store in a place protected from moisture and light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Buy ASA tablets p / o enteric soluble 75 mg No. 10×3